Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Quarterly results
|
|
PROTHENA CORP PUBLIC LTD CO (PRTA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/16/2023 |
8-K
| Appointed a new director |
| 09/01/2022 |
8-K
| Appointed a new director |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/21/2021 |
8-K
| Quarterly results |
| 05/20/2021 |
8-K
| Quarterly results |
| 05/22/2020 |
8-K
| Appointed a new director |
| 12/05/2019 |
8-K
| Appointed a new director |
| 07/03/2019 |
8-K
| Appointed a new director |
| 07/23/2013 |
8-K
| Appointed a new director|
Docs:
|
"PROTHENA WELCOMES NEW DIRECTOR TO ITS BOARD DUBLIN, Ireland - July 22, 2013 - Prothena Corporation plc , a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Dennis J. Selkoe, MD to its Board of Directors. Dr. Selkoe joins existing directors Lars Ekman, MD, PhD, Chairman; Dale Schenk, PhD, president and CEO; Richard Collier, Shane Cooke and Christopher Henney, PhD, DSc. “As the principal founding scientist of Athena Neurosciences and as a previous director of both Elan Corporation, plc and Athena, Dennis has extensive experience in leading biotech innovation. His wealth of scientific research and business knowledge and experience will be critical to us..." |
|
|
|